Clinical studies have shown that T1DM patients have an increased serum adiponectin level (Leth et al., 2008; Pereira et al., 2012), while the serum and hippocampal adiponectin levels were shown to decrease upon STZ administration in mice (Szkudelska et al., 2014). The gene discussed is ADIPOQ; the disease is type 1 diabetes mellitus.